Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension

Prevalence, Clinical Characteristics, and Outcomes Associated With Eccentric Versus Concentric Left Ventricular Hypertrophy in Heart Failure With Preserved Ejection Fraction

(2013) Daniel H. Katz et al.   AMERICAN JOURNAL OF CARDIOLOGY

Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension

(2013) Thiago Quinaglia et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

I posicionamento brasileiro sobre hipertensão arterial resistente

(2012)   Arquivos Brasileiros de Cardiologia

Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure

(2011) Valéria Nasser Figueiredo et al.   BLOOD PRESSURE

Sildenafil preserves diastolic relaxation after reduction by L-NAME and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles

(2011) Silvia Elaine Ferreira-Melo et al.   Clinics

Cardiac Uses of Phosphodiesterase-5 Inhibitors

(2011) Bryan G. Schwartz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension

(2010) Gil Fernando Salles et al.   AMERICAN HEART JOURNAL

Characteristics and Predictors of Obstructive Sleep Apnea in Patients With Systemic Hypertension

(2010) Luciano F. Drager et al.   AMERICAN JOURNAL OF CARDIOLOGY

PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure

(2010) Marco Guazzi et al.   Circulation-Heart Failure

Clinical Potential of Combined Organic Nitrate and Phosphodiesterase Type 5 Inhibitor in Treatment-Resistant Hypertension

(2010) James J. Oliver et al.   HYPERTENSION

cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action

(2010) S. H. Francis et al.   PHARMACOLOGICAL REVIEWS

Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice

(2009) Peter Pokreisz et al.   CIRCULATION

Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension

(2009) Robert Wolk et al.   HYPERTENSION

Aldosterone Excess or Escape: Treating Resistant Hypertension

(2009) Samira Ubaid-Girioli et al.   Journal of Clinical Hypertension

Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes

(2009) Honglan Wang et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes

(2008) Manling Zhang et al.   CELLULAR SIGNALLING

Resistant Hypertension: Diagnosis, Evaluation, and Treatment

(2008) David A. Calhoun et al.   CIRCULATION